Global Cord Blood (Global Cord Blood) Operating Income : $95.1 Mil (TTM As of Mar. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Global Cord Blood Operating Income?

Global Cord Blood's Operating Income for the three months ended in Mar. 2022 was $22.4 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 was $95.1 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Global Cord Blood's Operating Income for the three months ended in Mar. 2022 was $22.4 Mil. Global Cord Blood's Revenue for the three months ended in Mar. 2022 was $46.8 Mil. Therefore, Global Cord Blood's Operating Margin % for the quarter that ended in Mar. 2022 was 47.82%.

Global Cord Blood's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Global Cord Blood's annualized ROC % for the quarter that ended in Mar. 2022 was 21.05%. Global Cord Blood's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was 118.64%.

Global Cord Blood Operating Income Historical Data

The historical data trend for Global Cord Blood's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Cord Blood Operating Income Chart

Global Cord Blood Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Operating Income

Get a 7-Day Free Trial

44.30

56.86

79.63

83.69

95.97

Global Cord Blood Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Operating Income	Get a 7-Day Free Trial															22.77	24.37	24.85	23.51	22.40

Global Cord Blood Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $95.1 Mil.

Global Cord Blood (OTCPK:CORBF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Global Cord Blood's annualized ROC % for the quarter that ended in Mar. 2022 is calculated as:

	ROC % (Q: Mar. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2021 )	+	Invested Capital (Q: Mar. 2022 ))	/ count )
=	89.612 * ( 1 - 23.75% )	/	( (324.871	+	324.36)	/ 2 )
=	68.32915	/	324.6155
=	21.05 %

where

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1318.469	-	28.704	-	( 1021.308	-	max(0, 99.932	-	1064.826	+	1021.308	))
=	324.871

	Invested Capital		(Q: Mar. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1345.164	-	29.655	-	( 1049.867	-	max(0, 101.907	-	1093.056	+	1049.867	))
=	324.36

Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Global Cord Blood's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2021		Q: Mar. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	89.612	/	( ( (75.937 + max(-56.148, 0))	+	(75.133 + max(-67.348, 0)) )	/	2 )
=	89.612	/	( ( 75.937	+	75.133 )	/	2 )
=	89.612	/	75.535
=	118.64 %

where Working Capital is:

	Working Capital		(Q: Dec. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(24.19	+	7.44	+	11.888)	-	(28.704	+	70.961	+	0.0010000000000048)
=	-56.148

	Working Capital		(Q: Mar. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(25.424	+	7.231	+	1.8810000000001)	-	(29.655	+	72.229	+	0)
=	-67.348

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Global Cord Blood's Operating Margin % for the quarter that ended in Mar. 2022 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2022 )	/	Revenue (Q: Mar. 2022 )
	=	22.403	/	46.844
	=	47.82 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Global Cord Blood Operating Income Related Terms

Thank you for viewing the detailed overview of Global Cord Blood's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Global Cord Blood (Global Cord Blood) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Global Cord Blood Corp (OTCPK:CORBF) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Garden Road, 48th Floor, Bank of China Tower, Central, Hong Kong, HKG

Website

http://www.globalcordbloodcorp.com

Global Cord Blood Corp provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments and technologies such as cord blood transplants.

Executives

Kent C Mccarthy	10 percent owner, other: Mbr 13(d) grp own 10% plus	930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Private Equity Fund Ii Lp	10 percent owner	5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205
7-2010 Grat 5 Under Kent C. Mccarthy Grat Tr Dtd 4-23-2010	other: 13 (d) group owning > 10%	7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
7-2010 Grat 6 Under Kent C Mccarthy Grat Tr Dtd 4-23-2010	10 percent owner, other: Member of 13(d) group owning m	7335 COTTONWOOD, SHAWNEE KS 66216
Mccarthy Family Sd, Llc	10 percent owner, other: 13 (d) group owning > 10%	7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jhab Fund Ii, Llc	other: 13(d) group owning > 10%	7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jhab Management Ii, Llc	other: 13(d) group owning > 10%	7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jcf Co Lf, L.p.	other: 13(d) group owning > 10%	930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Capital Management Llc	other: Member of the group	13021 W 74TH ST, SHAWNEE KS 66216
Jayhawk China Fund Cayman Ltd	other: Member of the group	930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Private Equity Gp Ii, L.p.	10 percent owner	5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205
Jayhawk Private Equity, Llc	10 percent owner	5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205